Seres Therapeutics (NASDAQ:MCRB) Receives “Buy” Rating from Canaccord Genuity Group

Seres Therapeutics (NASDAQ:MCRB)‘s stock had its “buy” rating reiterated by equities researchers at Canaccord Genuity Group in a report issued on Thursday,Benzinga reports. They currently have a $10.00 price objective on the biotechnology company’s stock.

Several other analysts have also weighed in on MCRB. StockNews.com lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 13th. Chardan Capital reiterated a “buy” rating and issued a $1.25 price target on shares of Seres Therapeutics in a report on Wednesday. Finally, JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Down 7.2 %

MCRB opened at $0.55 on Thursday. The firm has a market capitalization of $93.56 million, a P/E ratio of -2.39 and a beta of 2.06. The firm’s 50 day moving average is $0.85 and its 200-day moving average is $0.92. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $2.05.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. During the same quarter last year, the business earned $0.36 EPS. Equities analysts expect that Seres Therapeutics will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of Seres Therapeutics by 22.5% in the third quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after purchasing an additional 255,014 shares during the period. State Street Corp grew its holdings in Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after buying an additional 43,700 shares in the last quarter. Providence Wealth Advisors LLC grew its holdings in Seres Therapeutics by 29.2% in the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after buying an additional 22,250 shares in the last quarter. FMR LLC increased its position in Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after acquiring an additional 140,096 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after acquiring an additional 222,771 shares in the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.